Document:

Exhibit 10.2

 

May 20, 2016

 

Continental Stock Transfer & Trust Company

17 Battery Place

New York, NY 10004

Attn: Steven Nelson

 

Re: Transfer of Ordinary Shares
of CB Pharma Acquisition Corp.

 

Dear Mr. Nelson:

 

Pursuant to that certain Share Escrow Agreement
(the “Escrow Agreement”) dated December 12, 2014 by and among CB Pharma Acquisition Corp. (the “Company”),
Continental Stock Transfer & Trust Company (the “Escrow Agent”), Fortress Biotech, Inc. (formerly Coronado
Biosciences, Inc.), Adam J. Chill, Arthur A. Kornbluth and Neil Herskowitz (collectively, the “Initial Shareholders”),
the Escrow Agent is currently holding in escrow the ordinary shares of the Company owned by each of the Initial Shareholders in
the amounts identified in Schedule A (the “Escrow Shares”).

 

The
Initial Shareholders have executed an agreement (the “Transfer Agreement”) of even date herewith pursuant
to which they have transferred each Initial Shareholders’ Escrow Shares in the amounts identified in Schedule A
in a private transaction to EJF Opportunities, LLC, Stephen B. Pudles, Jose M. Aldeanueva, Jeffrey J. Gutovich Profit Sharing
Plan and  Barry Rodgers (collectively the “Investors”), for aggregate consideration of $1.00. The Escrow
Shares will remain in escrow with you pursuant to the terms of the Escrow Agreement, but will be transferred to the name of
the Investors. As Escrow Agent, you acknowledge and agree not to enter into any control or other agreement relating to,
or deliver possession of, the Escrow Shares to any third party, other than the Investors, that could create or perfect
a security interest in the Escrow Shares.

 

Further, in connection with our agreement
to transfer the Escrow Shares to the Investors, we are attaching executed instruments of transfer with respect to the Escrow Shares.
Please kindly effect the transfer of the Escrow Shares to the Investors. The Investors are agreeing to be bound by the terms and
conditions of the Escrow Agreement and will deliver the appropriate instruments of transfer to the Escrow Agent.

 

[Remainder of page intentionally
left blank; signature page to follow.]

 

     

     

    

 

This letter shall serve as irrevocable instructions
from the Initial Shareholders to you as the Escrow Agent with respect to the transfer of the Escrow Shares and may not be altered
by any of us in the future, except upon termination of the Transfer Agreement in accordance with its terms

 

	 	Very truly yours,
	 	 
	 	INITIAL SHAREHOLDERS:
	 	 
	 	/s/ Lindsay A. Rosenwald
	 	Fortress Biotech, Inc.
	 	 
	 	/s/ Adam J. Chill
	 	Adam J. Chill
	 	 
	 	/s/ Arthur A. Kornbluth
	 	Arthur A. Kornbluth
	 	 
	 	/s/ Neil Herskowitz
	 	Neil Herskowitz

 

The undersigned acknowledge and consent
to the foregoing terms.

 

THE COMPANY:

 

CB PHARMA ACQUISITION CORP.

 

	By:	/s/ Lindsay A. Rosenwald	 
	 	Name:	Lindsay A. Rosenwald	 
	 	Title:	CEO	 

 

ESCROW AGENT:

 

CONTINENTAL STOCK TRANSFER & TRUST
COMPANY

 

	By:	/s/ Robert McMonagle	 
	 	Name:	Robert McMonagle	 
	 	Title:	Vice President	 

 

[Signature Page - Transfer Shares Release
Letter]

 

     

     

    

 

Schedule A

 

	Name of Shareholder	 	Escrow Shares being
 Transferred	 	 	Transferee
	 	 	 	 	 	 
	Fortress Biotech, Inc.	 	 	520,000	 	 	EJF Opportunities, LLC
	 	 	 	 	 	 	 
	Fortress Biotech, Inc.	 	 	260,000	 	 	Stephen B. Pudles
	 	 	 	 	 	 	 
	Fortress Biotech, Inc.	 	 	130,000	 	 	Jose M. Aldeanueva
	 	 	 	 	 	 	 
	Fortress Biotech, Inc.	 	 	110,000	 	 	Jeffrey J. Gutovich Profit Sharing Plan
	 	 	 	 	 	 	 
	Adam J. Chill	 	 	10,000	 	 	Jeffrey J. Gutovich Profit Sharing Plan
	 	 	 	 	 	 	 
	Arthur A. Kornbluth	 	 	10,000	 	 	Jeffrey J. Gutovich Profit Sharing Plan
	 	 	 	 	 	 	 
	Neil Herskowitz	 	 	10,000	 	 	Barry RodgersExhibit 10.3

 

CB Pharma Acquisition Corp.

3 Columbus Circle, 15th Floor

New York, New York 10019

Attention: Lindsay A. Rosenwald

 

EJF Opportunities, LLC

Stephen B. Pudles

Jose M. Aldeanueva

Jeffrey J. Gutovich Profit Sharing Plan

Barry Rodgers 

 

Dear Sirs:

 

Pursuant to that certain Registration Rights Agreement (the
“RRA”), dated as of December 12, 2014, by and among CB Pharma Acquisition Corp., a Cayman Islands company (the
“Company”), and the respective undersigned parties (each, individually, a “Shareholder”,
and collectively, the “Shareholders”), the Company has granted the Shareholders certain registration rights
(the “Registration Rights”) with respect to the ordinary shares of the Company (the “Insider Shares”)
purchased by the Shareholders from the Company prior to the Company’s initial public offering.

 

The Shareholders have executed an agreement (the “Transfer
Agreement”) of even date herewith pursuant to which the Shareholders have transferred the Insider Shares, for aggregate
consideration of $1.00, to EJF Opportunities, LLC, Stephen B. Pudles, Jose M. Aldeanueva, Jeffrey J. Gutovich Profit Sharing Plan
and Barry Rodgers  (the “Investors”), in the amounts identified in Schedule A.  In connection
with the transfer of the Insider Shares, the Shareholders desire to assign their Registration Rights with respect to the Insider
Shares to the Investors in accordance with Section 6.2 of the RRA, and the Company has agreed to consent to such assignment. Accordingly,
the Shareholders’ Registration Rights with respect to such securities shall be assigned to the Investors as of the date hereof.  The
Shareholders shall maintain their Registration Rights with respect to any other securities of the Company not transferred to the
Investors pursuant to the Transfer Agreement.  

 

[Remainder
of page intentionally left blank; signature page to follow.]

 

     

     

    

 

 

 

	 	Very truly yours,	 
	 	 	 
	 	SHAREHOLDERS:	 
	 	 	 
	 	/s/ Lindsay A. Rosenwald	 
	 	Fortress Biotech, Inc.	 
	 	 	 
	 	/s/ Adam J. Chill	 
	 	Adam J. Chill	 
	 	 	 
	 	/s/ Arthur A. Kornlbuth	 
	 	Arthur A. Kornlbuth	 
	 	 	 
	 	/s/ Neil Herskowitz	 
	 	Neil Herskowitz	 

 

The undersigned acknowledges and consents to the foregoing terms.

 

COMPANY:

 

CB PHARMA ACQUISITION CORP.

 

	By:	/s/ Lindsay A. Rosenwald	 
	 	Name: Lindsay A. Rosenwald	 
	 	Title: Chief Executive Officer	 

 

[Signature Page - Registration Rights Assignment
Letter]

 

     

     

    

 

Schedule A

 

	Name of Shareholder     	 	Escrow Shares being

Transferred	 	Transferee
	 	 	 	 	 
	Fortress Biotech, Inc.	 	520,000	 	EJF Opportunities, LLC
	 	 	 	 	 
	Fortress Biotech, Inc.	 	260,000	 	Stephen B. Pudles
	 	 	 	 	 
	Fortress Biotech, Inc.	 	130,000	 	Jose M. Aldeanueva
	 	 	 	 	 
	Fortress Biotech, Inc.	 	110,000	 	Jeffrey J. Gutovich Profit Sharing Plan
	 	 	 	 	 
	Adam J. Chill	 	10,000	 	Jeffrey J. Gutovich Profit Sharing Plan
	 	 	 	 	 
	Arthur A. Kornbluth	 	10,000	 	Jeffrey J. Gutovich Profit Sharing Plan
	 	 	 	 	 
	Neil Herskowitz	 	10,000	 	Barry RodgersExhibit 10.4

 

May 20, 2016

 

CB Pharma
Acquisition Corp.

3 Columbus
Circle, 15th Floor

New York,
New York 10019

 

Gentlemen:

 

As a condition to the consummation of the
transactions contemplated by that certain agreement (the “Transfer Agreement”), dated the date hereof,
by and among the undersigned, CB Pharma Acquisition Corp. (the “Company”), Fortress Biotech, Inc., Adam
J. Chill, Arthur A. Kornbluth and Neil Herskowitz (collectively, the “Sellers”), the undersigned hereby
agrees as follows (certain capitalized terms used herein are defined in paragraph 13 hereof):.

 

1.             If
the Company solicits approval of its shareholders of a Business Combination, the undersigned will vote all Ordinary Shares beneficially
owned by him in favor of such Business Combination.

 

2.             (a)          In the event that the Company fails to consummate a Business Combination within the required time period set forth in the Company’s
Amended and Restated Memorandum and Articles of Association as the same may be amended from time to time, the undersigned shall
take all reasonable steps to (i) cause the Trust Fund to be liquidated and distributed to the holders of IPO Shares and (ii) cause
the Company to liquidate as soon as reasonably practicable.

 

(b)          The
undersigned hereby waives any and all right, title, interest or claim of any kind in or to any distribution of the Trust Fund and
any remaining net assets of the Company as a result of such liquidation with respect to any Insider Shares beneficially owned by
the undersigned (“Claim”) and hereby waives any Claim the undersigned may have in the future as a result
of, or arising out of, any contracts or agreements with the Company and will not seek recourse against the Trust Fund for any reason
whatsoever. The undersigned acknowledges and agrees that there will be no distribution from the Trust Fund with respect to any
Rights or Warrants which the undersigned may own, all of which will terminate on the Company’s liquidation.

 

[(c)          In
the event of the liquidation of the Trust Fund, the undersigned agrees to indemnify and hold harmless the Company against any and
all loss, liability, claims, damage and expense whatsoever (including, but not limited to, any and all legal or other expenses
reasonably incurred in investigating, preparing or defending against any litigation, whether pending or threatened, or any claim
whatsoever) which the Company may become subject as a result of any claim by any vendor or other person who is owed money by the
Company for services rendered or products sold or contracted for, or by any target business, but only to the extent necessary to
ensure that such loss, liability, claim, damage or expense does not reduce the amount of funds in the Trust Fund; provided
that such indemnity shall not apply if such vendor or prospective target business executes an agreement waiving any claims against
the Trust Fund.]

 

     

     

    

 

3.             The
undersigned acknowledges that the Insider Shares will be held in escrow pursuant to the terms of that certain Share Escrow Agreement
dated December 12, 2014 which the Company has entered into.

 

4.             In
order to minimize potential conflicts of interest which may arise from multiple affiliations, the undersigned agrees to present
to the Company for its consideration, prior to presentation to any other person or entity, any suitable opportunity to acquire
a target business, until the earlier of the consummation by the Company of a Business Combination or the liquidation of the Company,
subject to any pre-existing fiduciary and contractual obligations the undersigned might have.

 

5.             The
undersigned acknowledges and agrees that prior to entering into a Business Combination with a target business that is affiliated
with any Insiders of the Company or their affiliates, such transaction must be approved by a majority of the Company’s disinterested
independent directors and the Company must obtain an opinion from an independent investment banking firm or another firm that regularly
provides similar opinions regarding the type of business that the Company is seeking to acquire that such Business Combination
is fair to the Company’s unaffiliated shareholders from a financial point of view.

 

6.             Neither
the undersigned nor any affiliate of the undersigned will be entitled to receive and will not accept any compensation or other
cash payment for services rendered prior to, or in order to effectuate, the consummation of the Business Combination; provided
that the Company shall be allowed to (i) repay working capital loans made by the undersigned to the Company in cash upon consummation
of the Business Combination or, at the undersigned’s discretion, with respect to up to an aggregate of $175,000 of working
capital loans from all lenders, by converting such loans into units at a price of $10.00 per unit, as more fully described in the
Registration Statement, and (ii) reimburse the undersigned and any affiliate of the undersigned for their out-of-pocket expenses
incurred in connection with identifying, investigating and consummating a Business Combination.

 

7.             Neither
the undersigned nor any affiliate of the undersigned will be entitled to receive or accept a finder’s fee or any other compensation
in the event the undersigned, any member of the family of the undersigned or any affiliate of the undersigned originates a Business
Combination.

 

8.             The
undersigned agrees to be an officer and/or director of the Company until consummation by the Company of a Business Combination
or the liquidation of the Company. The undersigned represents and warrants that:

 

    	 	2	 

     

    

 

		(a)	he has never had a petition under the federal bankruptcy
laws or any state insolvency law been filed by or against (i) him or any partnership in which he was a general partner at or within
two years before the time of filing; or (ii) any corporation or business association of which he was an executive officer at or
within two years before the time of such filing;

 

		(b)	he has never had a receiver, fiscal agent or similar officer
been appointed by a court for his business or property, or any such partnership;

 

		(c)	he has never been convicted of fraud in a civil or criminal
proceeding;

 

		(d)	he/ has never been convicted in a criminal proceeding or
named the subject of a pending criminal proceeding (excluding traffic violations and minor offenses);

 

		(e)	he has never been the subject of any order, judgment or
decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining
or otherwise limiting him from (i) acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity
pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission
(“CFTC”) or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer
in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association
or insurance company, or from engaging in or continuing any conduct or practice in connection with any such activity; or (ii)
engaging in any type of business practice; or (iii) engaging in any activity in connection with the purchase or sale of any
security or commodity or in connection with any violation of federal or state securities or federal commodities laws;

 

		(f)	he has never been the subject of any order, judgment or
decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending or otherwise limiting
for more than 60 days his right to engage in any activity described in 9(e)(i) above, or to be associated with persons engaged
in any such activity;

 

		(g)	he has never been found by a court of competent jurisdiction
in a civil action or by the SEC to have violated any federal or state securities law, where the judgment in such civil action
or finding by the SEC has not been subsequently reversed, suspended or vacated;

 

		(h)	he has never been found by a court of competent jurisdiction
in a civil action or by the CFTC to have violated any federal commodities law, where the judgment in such civil action or finding
by the CFTC has not been subsequently reversed, suspended or vacated;

 

    	 	3	 

     

    

 

		(i)	he has never been the subject of, or a party to, any Federal
or State judicial or administrative order, judgment, decree or finding, not subsequently reversed, suspended or vacated, relating
to an alleged violation of (i) any Federal or State securities or commodities law or regulation, (ii) any law or regulation respecting
financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement
or restitution, civil money penalty or temporary or permanent cease-and desist order, or removal or prohibition order or (iii)
any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity;

 

		(j)	he has never been the subject of, or party to, any sanction
or order, not subsequently reversed, suspended or vacated, or any self-regulatory organization, any registered entity, or any
equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated
with a member;

 

		(k)	he has never been convicted of any felony or misdemeanor:
(i) in connection with the purchase or sale of any security; (ii) involving the making of any false filing with the SEC; or (iii)
arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment advisor
or paid solicitor of purchasers of securities;

 

		(l)	he was never subject to a final order of a state securities
commission (or an agency of officer of a state performing like functions); a state authority that supervises or examines banks,
savings associations, or credit unions; a state insurance commission (or an agency or officer of a state performing like functions);
an appropriate federal banking agency; the Commodity Futures Trading Commission; or the National Credit Union Administration that
is based on a violation of any law or regulation that prohibits fraudulent, manipulative, or deceptive conduct;

 

		(m)	he has never been subject to any order, judgment or decree
of any court of competent jurisdiction, that, at the time of such sale, restrained or enjoined him from engaging or continuing
to engage in any conduct or practice: (i) in connection with the purchase or sale of any security; (ii) involving the making of
any false filing with the SEC; or (iii) arising out of the conduct of the business of an underwriter, broker, dealer, municipal
securities dealer, investment adviser or paid solicitor of purchasers of securities;

 

		(n)	he has never been subject to any order of the SEC that
orders him to cease and desist from committing or causing a future violation of: (i) any scienter-based anti-fraud provision of
the federal securities laws, including, but not limited to, Section 17(a)(1) of the Securities Act, Section 10(b) of the Exchange
Act and Rule 10b-5 thereunder, and Section 206(1) of the Advisers Act or any other rule or regulation thereunder; or (ii) Section
5 of the Securities Act;

 

    	 	4	 

     

    

 

		(o)	he has never been named as an underwriter in any registration
statement or Regulation A offering statement filed with the SEC that was the subject of a refusal order, stop order, or order
suspending the Regulation A exemption, or is, currently, the subject of an investigation or proceeding to determine whether a
stop order or suspension order should be issued;

 

		(p)	he has never been subject to a United States Postal Service
false representation order, or is currently subject to a temporary restraining order or preliminary injunction with respect to
conduct alleged by the United States Postal Service to constitute a scheme or device for obtaining money or property through the
mail by means of false representations;

 

		(q)	he is not subject to a final order of a state securities
commission (or an agency of officer of a state performing like functions); a state authority that supervises or examines banks,
savings associations, or credit unions; a state insurance commission (or an agency or officer of a state performing like functions);
an appropriate federal banking agency; the Commodity Futures Trading Commission; or the National Credit Union Administration that
bars the undersigned from: (i) association with an entity regulated by such commission, authority, agency or officer; (ii) engaging
in the business of securities, insurance or banking; or (iii) engaging in savings association or credit union activities;

 

		(r)	he is not subject to an order of the SEC entered pursuant
to section 15(b) or 15B(c) of the Securities Exchange Act of 1934 (the “Exchange Act”) or section 203(e) or 203(f)
of the Investment Advisers Act of 1940 (the “Advisers Act”) that: (i) suspends or revokes the undersigned’s
registration as a broker, dealer, municipal securities dealer or investment adviser; (ii) places limitations on the activities,
functions or operations of, or imposes civil money penalties on, such person; or (iii) bars the undersigned from being associated
with any entity or from participating in the offering of any penny stock; and

 

		(s)	he has never been suspended or expelled from membership
in, or suspended or barred from association with a member of, a securities self-regulatory organization (e.g., a registered national
securities exchange or a registered national or affiliated securities association) for any act or omission to act constituting
conduct inconsistent with just and equitable principles of trade.

 

9.          The
undersigned has full right and power, without violating any agreement by which it is bound, to enter into this letter agreement
and to serve as an officer and/or director of the Company.

 

10.         The
undersigned hereby waives his right to exercise conversion rights with respect to any shares of the Ordinary Shares owned or to
be owned by the undersigned, directly or indirectly, whether purchased by the undersigned prior to the IPO, in the IPO or in the
aftermarket, and agrees that he will not seek conversion with respect to or otherwise sell, such shares in connection with any
vote to approve a Business Combination with respect thereto.

 

    	 	5	 

     

    

 

11.         In
the event that the Company does not consummate a Business Combination and must liquidate and its remaining net assets are insufficient
to complete such liquidation, the undersigned agrees to advance such funds necessary to complete such liquidation and agrees not
to seek repayment for such expenses.

 

12.         This
letter agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without
giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.
The undersigned hereby (i) agrees that any action, proceeding or claim against him arising out of or relating in any way to this
letter agreement (a “Proceeding”) shall be brought and enforced in the courts of the State of New York
of the United States of America for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive, (ii) waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum
and (iii) irrevocably agrees to appoint Graubard Miller as agent for the service of process in the State of New York to receive,
for the undersigned and on his behalf, service of process in any Proceeding.

 

13.         As
used herein, (i) a “Business Combination” shall mean a merger, share exchange, asset acquisition, share
purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities; (ii)
“Insiders” shall mean all former and current officers and directors of the Company and all shareholders
of the Company that acquired Ordinary Shares of the Company prior to the IPO, or, if after the IPO, in a private transfer from
another former or current officer or director of the Company, or from a shareholder that purchased such Ordinary Shares prior to
the IPO; (iii) “Insider Shares” shall mean all of the Ordinary Shares of the Company issued prior to
the IPO; (iv) “IPO Shares” shall mean the Ordinary Shares issued in the Company’s IPO; (v) “Memorandum
and Articles of Association” shall mean the Company’s memorandum and articles of association, as the same may
be amended and restated from time to time; (vi) “Registration Statement” means the registration statement
on Form S-1 filed by the Company with respect to the IPO; and (vii) “Trust Fund” shall mean the trust
fund into which a portion of the net proceeds of the Company’s IPO were deposited.

 

14.         Any
notice, consent or request to be given in connection with any of the terms or provisions of this letter agreement shall be in writing
and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery
or facsimile transmission.

 

15.         No
party hereto may assign either this letter agreement or any of its rights, interests, or obligations hereunder without the prior
written consent of the other party. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall
not operate to transfer or assign any interest or title to the purported assignee. This letter agreement shall be binding on the
parties hereto and any successors and assigns thereof.

 

    	 	6	 

     

    

 

	 	 
	 	Print Name of Insider
	 	 
	 	 
	 	Signature

 

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]